Abstract
Multiple sclerosis (MS) is an immune-mediated and degenerative disease of nervous system, which affects mostly young adults. Vitamin D deficiency is a well-known environmental risk factor for MS and is considerable in terms of immediate clinical implications. In addition to its classical action on regulation of bone homeostasis, vitamin D may have a potent impact on cytokine profiles and neuro-inflammation. Given the immunomodulatory effects of vitamin D and its high rate of deficiency in MS patients, prescribing vitamin D is a remarkable issue in MS. The results from several experimental and clinical studies indicate that vitamin D supplementation may ameliorate the inflammation during the relapse phase and attenuate disease progression. We present the experimental and clinical studies, which assessed the effects of vitamin D on the pathophysiology, prevalence and management of MS. The authors also discuss current recommendations on prescription of this vitamin to MS patients.
Original language | English (US) |
---|---|
Pages (from-to) | 327-333 |
Number of pages | 7 |
Journal | Acta Neurologica Belgica |
Volume | 112 |
Issue number | 4 |
DOIs | |
State | Published - Dec 2012 |
Keywords
- Demyelinating
- Multiple sclerosis
- Prevention
- Vitamin D
ASJC Scopus subject areas
- Clinical Neurology